Current optimization of combined therapy for chronic obstructive pulmonary disease


Cite item

Full Text

Abstract

Testing the new combined bronchodilator Anoro Ellipta in different clinical trials gives proof to its high clinical efficacy and safety in chronic obstructive pulmonary disease. The drug contains the molecules of a sustained-release selective β2-adrenergic receptor agonist (vilanterol) and a muscarinic cholinergic receptor antagonist (umeclidinium bromide). The bronchodilating mechanisms of umeclidinium bromide are in the competitive inhibition of the binding of acetylcholine with muscarinic acetylcholine receptors of airway smooth muscles whereas in those of vilanterol are in that with the stimulation of intracellular adenylate cyclase. On days 1 and 24 after inhalation of the first dose of vilanterol and umeclidinium bromide, there was a significant increase in the forced expiratory volume in one second as compared to placebo. No clinical effects on QT interval on an electrocardiogram and cardiac rhythm were found. The benefits of an inhalation device (Ellipta) are its innovation design ensuring the effective delivery of an aerosol dose into the airway, convenience, and simplicity.

About the authors

E N Popova

References

  1. Global initiative for chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. Доступно по: http://www.goldcopd.org/guidelines-global-strategy-for-diag nisis-management.pdf
  2. Чучалин А.Г. Хроническая обструктивная болезнь легких — 2009: итоги первой декады нового тысячелетия. Consilium medicum. 2009;Экстравыпуск:3.
  3. Pasqua F, Biscione G, Crigna G, Auciello L, Cazzola M. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. Respir Med. 2010;104:412-417.
  4. Global Strategy for Diagnosis, Management, and Prevention of COPD (GOLD) 2014. Доступно по: www.goldcopd.org.
  5. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med. 2003;97(Suppl C):S3-14.
  6. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest. 2003;123(5):1684-1692.
  7. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308-1331. doi: 10.1183/09031936.00166410.
  8. Baddar S, Jayakrishnan B, Al-Rawas OA. Asthma control: importance of compliance and inhaler technique assessments. J Asthma. 2014;51(4):429-434. doi: 10.3109/02770903.2013.871558.
  9. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat M, Versnel J, Shanahan ER, Hillyer EV, Tunsäter A, Bjermer L. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008;102:1681-1693.
  10. Small M, Anderson P, Vickers A, Kay S, Fermer S. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011;28:202-212.
  11. Melani AS, Bonavia M. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930-938.
  12. Vestbo J, Anderson JA. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939-943.
  13. Gloeckl R. Practical recommendations for exercise training in patients with COPD. Eur Respir Rev. 2013;22:178-186.
  14. Casanova C. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am Jrespir Crit Care Med. 2005;171:591-597.
  15. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
  16. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106:970-979.
  17. US Food and Drug Administration. FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease [press release]. December 18, 2013. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htm. Accessed: December 30, 2013.
  18. Donohue J, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-1546.
  19. Maltais F. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8:169.
  20. George J, Kong DCM, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest. 2005;128:3198-3204.
  21. Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J COPD. 2011;6:353-363.
  22. Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;14:109-116.
  23. Rice KL, Dewan N, Bloomfield HE, Grill J, Schult TM, Nelson DB et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010;182(7):890-896.
  24. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72-81.
  25. Calverley P. New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease. Semin Respir Crit Care Med. 2015;36(4):523-542.
  26. Hanania NA, Feldman G, Zachgo W et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119-127.
  27. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R et al. Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease. JAMA Intern Med. 2013;1-9.
  28. Decramer M. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomized controlled trials. The Lancet RespiratoryMedicine. 2014;2(6):472-486.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies